Get the Stockscreener App
69.77
0.29%
0.20
After Hours:
69.77
Soleno Therapeutics Inc stock is traded at $69.77, with a volume of 556.57K.
It is up +0.29% in the last 24 hours and down -14.53% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
See More
Previous Close:
$69.57
Open:
$69.82
24h Volume:
556.57K
Relative Volume:
0.42
Market Cap:
$3.71B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-23.28
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
+3.10%
1M Performance:
-14.53%
6M Performance:
+55.08%
1Y Performance:
+39.78%
1-Day Range:
$67.51
$70.06
1-Week Range:
$65.85
$70.12
52-Week Range:
$41.50
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
69.77 | 3.70B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Analyzing Soleno Therapeutics Inc. with multi timeframe chartsSell Signal & Verified Short-Term Trading Plans - Newser
Ranking Soleno Therapeutics Inc. among high performing stocks via toolsWeekly Investment Summary & Fast Entry High Yield Stock Tips - Newser
ROSEN, LEADING INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action InvestigationSLNO - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - GlobeNewswire Inc.
Published on: 2025-09-06 01:23:59 - خودرو بانک
CEO Moves: What is Soleno Therapeutics Inc.’s market positionWeekly Market Outlook & Daily Technical Forecast Reports - خودرو بانک
What is the long term forecast for Soleno Therapeutics Inc. stockJuly 2025 Trade Ideas & High Accuracy Swing Entry Alerts - خودرو بانک
Does Soleno Therapeutics Inc. have declining or rising EPSJuly 2025 Decliners & Comprehensive Market Scan Insights - خودرو بانک
Will Soleno Therapeutics Inc. continue its uptrendJuly 2025 Gainers & Technical Pattern Based Buy Signals - Newser
Is Soleno Therapeutics Inc. a momentum stockJuly 2025 Review & Free Technical Confirmation Trade Alerts - خودرو بانک
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action InvestigationSLNO - The Malaysian Reserve
Regulatory and Legal Risks in Biotech Investing: Lessons from Soleno Therapeutics (SLNO) - AInvest
Can Soleno Therapeutics Inc. sustain its profitabilityJuly 2025 Earnings & Real-Time Buy Signal Alerts - خودرو بانک
News impact scoring models applied to Soleno Therapeutics Inc.July 2025 Decliners & Consistent Growth Equity Picks - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Connect - ACCESS Newswire
Understanding Soleno Therapeutics Inc.’s price movement2025 Retail Activity & Safe Entry Zone Identification - Newser
Best data tools to analyze Soleno Therapeutics Inc. stockWeekly Profit Analysis & AI Forecasted Stock Moves - Newser
Using fundamentals and technicals on Soleno Therapeutics Inc.Weekly Profit Analysis & Low Risk Entry Point Guides - Newser
Soleno Therapeutics Inc. stock trendline breakdown2025 Trade Ideas & Weekly Setup with ROI Potential - Newser
Is Soleno Therapeutics Inc. showing signs of accumulationJuly 2025 Opening Moves & Intraday High Probability Alerts - Newser
Analyzing drawdowns of Soleno Therapeutics Inc. with statistical toolsJuly 2025 Setups & Expert Verified Stock Movement Alerts - Newser
Will Soleno Therapeutics Inc. benefit from macro trendsWeekly Trade Recap & Weekly Hot Stock Watchlists - Newser
Soleno Therapeutics: A High-Stakes Play in Rare Diseases with Metabolic Potential - AInvest
Transcript : Soleno Therapeutics, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-04-2025 01 - MarketScreener
Published on: 2025-09-05 00:04:12 - Newser
understanding soleno therapeutics inc.’s price movementJuly 2025 Macro Moves & Daily Growth Stock Investment Tips - Newser
What are the risks of holding Soleno Therapeutics Inc.Trade Performance Summary & AI Driven Price Forecasts - خودرو بانک
Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bragar Eagel & Squire, P.C. Is Investigating Fortinet, - GlobeNewswire
Soleno Therapeutics' Strategic Position in the 2025 Healthcare Innovation Landscape: A Deep Dive into Pipeline Differentiation and Market Readiness - AInvest
Soleno Therapeutics: Navigating the Diabetes Therapeutics Landscape Through PWS-Centric Innovation - AInvest
Advanced analytics toolkit walkthrough for Soleno Therapeutics Inc.Market Trend Summary & Free Weekly Watchlist of Top Performers - Newser
Why Soleno Therapeutics Inc. stock is on top investor watchlistsQuarterly Earnings Summary & Weekly Momentum Stock Picks - Newser
How cyclical is Soleno Therapeutics Inc.’s revenue streamEarnings Recap Summary & Free Safe Capital Growth Stock Tips - خودرو بانک
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Is it too late to sell Soleno Therapeutics Inc.Portfolio Update Report & Verified Momentum Stock Alerts - Newser
Is Soleno Therapeutics Inc. stock bottoming outQuarterly Profit Review & Step-by-Step Swing Trade Plans - Newser
What institutional flow reveals about Soleno Therapeutics Inc.July 2025 Recap & Daily Price Action Insights - Newser
Soleno Therapeutics, Inc. $SLNO Shares Bought by Northern Trust Corp - Defense World
Is Soleno Therapeutics Inc. a good stock for dollar cost averaging2025 Year in Review & Low Drawdown Trading Strategies - خودرو بانک
Published on: 2025-09-03 01:49:16 - Newser
Regression analysis insights on Soleno Therapeutics Inc. performance2025 EndofYear Setup & Trade Opportunity Analysis Reports - Newser
What is the next catalyst for Soleno Therapeutics Inc.July 2025 Decliners & AI Forecast Swing Trade Picks - خودرو بانک
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
When is the best time to exit Soleno Therapeutics Inc.July 2025 Breakouts & Daily Volume Surge Signals - Newser
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):